What Considerations Are There in Prescribing a Medical Cannabis Card?
Discussion
Cannabis is a plant which has many pharmacologically active compounds with THC or tetrahydrocannabinol and cannabidiol (CBD) being the most studied. For this case, medical cannabis will be used to describe different forms of the plant used to pharmacologically treat a variety of medical conditions.
Medical cannabis has been proposed and mainly studied in adult populations. Qualifying conditions for use of medical cannabis in this author’s US state currently include: ”
Cancer – if the illness or its treatment produces one or more of the following: severe or chronic pain, nausea or severe vomitin...
Source: PediatricEducation.org - January 31, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
B12 deficiency: Two warning signs on the head and ears that you are lacking the nutrient
B12 deficiency may come about following surgery to address a number of bowel conditions, such as Crohn's disease, ulcerative colitis or bowel cancer. Here are the warning signs. (Source: Daily Express - Health)
Source: Daily Express - Health - January 3, 2022 Category: Consumer Health News Source Type: news
Vedolizumab Doesn't Increase Risk of C diff in Ulcerative Colitis Vedolizumab Doesn't Increase Risk of C diff in Ulcerative Colitis
Vedolizumab ' s effects in the intestines have led to concerns that the antibody could increase the risk of C difficile infection in patients with ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 28, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Donor-Derived Strains Predict FMT Response for Ulcerative Colitis Donor-Derived Strains Predict FMT Response for Ulcerative Colitis
Core strains from human donors limited ulcerative colitis in mouse models, which may shape strategies for more effective microbial therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 6, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Upadacitinib Delivers Rapid Response in Ulcerative Colitis Upadacitinib Delivers Rapid Response in Ulcerative Colitis
Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2021 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Consumer Health: Living with Crohn's disease and colitis
Crohn ’s and Colitis Awareness Week will be observed Dec. 1–7, which makes this a good time to learn about living with these disorders. Researchers estimate that more than half a million people in the U.S. have Crohn’s disease, and 600,000 to 900,000 people in the U.S. have ulcerative colitis, accor ding to the National Institute of Diabetes and Digestive and Kidney Diseases. Inflammatory bowel disease is an umbrella term used to describe disorders that involve chronic… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2021 Category: Databases & Libraries Source Type: news
What Is the Best Diet for Someone With Ulcerative Colitis?
Title: What Is the Best Diet for Someone With Ulcerative Colitis?Category: Diseases and ConditionsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 11/30/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 30, 2021 Category: Nutrition Source Type: news
When Do You Need Ulcerative Colitis Hospitalization?
Title: When Do You Need Ulcerative Colitis Hospitalization?Category: Diseases and ConditionsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 11/30/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 30, 2021 Category: Nutrition Source Type: news
Etrolizumab Down but Not Out for Ulcerative Colitis: Studies Etrolizumab Down but Not Out for Ulcerative Colitis: Studies
Etrolizumab does not appear to be effective as induction or maintenance therapy for moderately to severely active ulcerative colitis, according to results of five phase 3 trials.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 29, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
What Foods Trigger Ulcerative Colitis?
Title: What Foods Trigger Ulcerative Colitis?Category: Diseases and ConditionsCreated: 11/29/2021 12:00:00 AMLast Editorial Review: 11/29/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 29, 2021 Category: Nutrition Source Type: news
How Do I Know if My Ulcerative Colitis Is Flaring?
Title: How Do I Know if My Ulcerative Colitis Is Flaring?Category: Diseases and ConditionsCreated: 11/23/2021 12:00:00 AMLast Editorial Review: 11/23/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 23, 2021 Category: Nutrition Source Type: news
Can Ulcerative Colitis Be Healed?
Title: Can Ulcerative Colitis Be Healed?Category: Diseases and ConditionsCreated: 11/22/2021 12:00:00 AMLast Editorial Review: 11/22/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 22, 2021 Category: Nutrition Source Type: news
Prior Biologic Exposure No Barrier for Ozanimod in Colitis Prior Biologic Exposure No Barrier for Ozanimod in Colitis
Ozanimod is significantly more effective than placebo for treating patients with moderate to severe ulcerative colitis, regardless of prior biologic exposure, based on results of a phase 3 trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Patient Risk Key to Timing Biologics in IBD Patient Risk Key to Timing Biologics in IBD
The risk for complications and disease progression should be the main factors in the decision to initiate biologics for patients with Crohn ' s disease and ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 18, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
